United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,237 shares of the company’s stock in a transaction that occurred on Thursday, June 29th. The stock was sold at an average price of $130.92, for a total value of $161,948.04. Following the completion of the transaction, the chief executive officer now owns 1,377 shares of the company’s stock, valued at approximately $180,276.84. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of United Therapeutics Corporation (NASDAQ UTHR) traded up 2.60% during midday trading on Friday, reaching $128.35. The company’s stock had a trading volume of 583,874 shares. United Therapeutics Corporation has a 12 month low of $110.90 and a 12 month high of $169.89. The stock has a 50-day moving average of $130.85 and a 200 day moving average of $136.71. The company has a market cap of $5.76 billion, a price-to-earnings ratio of 14.88 and a beta of 1.52.
United Therapeutics Corporation (NASDAQ:UTHR) last posted its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.61 by $4.86. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.57%. The business had revenue of $444.60 million during the quarter, compared to analyst estimates of $391.53 million. During the same period in the previous year, the firm posted $4.42 earnings per share. The firm’s revenue was up 7.8% on a year-over-year basis. On average, analysts predict that United Therapeutics Corporation will post $14.40 earnings per share for the current fiscal year.
United Therapeutics Corporation declared that its board has initiated a share repurchase plan on Thursday, April 27th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the biotechnology company to purchase up to 4.6% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s management believes its shares are undervalued.
ILLEGAL ACTIVITY WARNING: This news story was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.chaffeybreeze.com/2017/07/29/martine-a-rothblatt-sells-1237-shares-of-united-therapeutics-corporation-nasdaquthr-stock-updated-updated-updated.html.
A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. CT Financial Advisors LLC boosted its position in United Therapeutics Corporation by 21.8% in the first quarter. CT Financial Advisors LLC now owns 4,940 shares of the biotechnology company’s stock worth $669,000 after buying an additional 884 shares during the last quarter. Opus Point Partners Management LLC boosted its position in United Therapeutics Corporation by 10.4% in the fourth quarter. Opus Point Partners Management LLC now owns 1,951 shares of the biotechnology company’s stock worth $280,000 after buying an additional 183 shares during the last quarter. Teachers Advisors LLC boosted its position in United Therapeutics Corporation by 34.9% in the fourth quarter. Teachers Advisors LLC now owns 78,089 shares of the biotechnology company’s stock worth $11,200,000 after buying an additional 20,204 shares during the last quarter. Origin Asset Management LLP boosted its position in United Therapeutics Corporation by 141.6% in the fourth quarter. Origin Asset Management LLP now owns 151,251 shares of the biotechnology company’s stock worth $21,694,000 after buying an additional 88,650 shares during the last quarter. Finally, Norges Bank acquired a new position in United Therapeutics Corporation during the fourth quarter worth about $63,975,000.
Several equities analysts have recently commented on UTHR shares. ValuEngine cut United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 2nd. BidaskClub upgraded United Therapeutics Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 16th. Credit Suisse Group restated an “underperform” rating and set a $120.00 price objective on shares of United Therapeutics Corporation in a research note on Monday, April 3rd. Jefferies Group LLC reaffirmed a “sell” rating and issued a $105.00 target price on shares of United Therapeutics Corporation in a research report on Thursday, June 8th. Finally, J P Morgan Chase & Co set a $125.00 target price on United Therapeutics Corporation and gave the stock a “hold” rating in a research report on Tuesday, April 11th. Five analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $134.50.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.